Atossa Therapeutics, Inc.

ATOS Healthcare Biotechnology

In the quarter to June 2026, EPS grew 9.48% and free cash flow fell 32.9%, each against the same quarter a year earlier.

2.91 0.26 +9.81%
Market cap
$26.4M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
−15.64
Beneish M
n/a
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Current Ratio
5.53 14.99 17.61 21.23 45.18 2.73 10.83 3.96 6.45 3.11
Net Debt/EBITDA
1.12 2.58 2.82 4.01 6.66 2.72 0.74 0.92 0.97 0.40
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating CF/Net income
0.86 0.82 0.70 0.77 0.80 0.52 0.53 0.39 0.62 0.84
Capex/Depreciation
(1.44) (1.12) (0.61) (3.37) (0.39) (0.19) (0.14) (2.51) 0.00 (0.03)
ROE
(62.74%) (31.39%) (28.80%) (21.10%) (25.11%) (114.42%) (182.33%) (342.46%) (213.05%) (186.26%)
ROA
(56.06%) (29.54%) (27.39%) (20.36%) (22.39%) (77.90%) (131.55%) (230.17%) (173.71%) (122.62%)
ROIC
0.00% (6,100.04%) (801.74%) (248.52%) (777.78%) 0.00% (2,321.12%) 0.00% 0.00% (35,321.81%)
Return on Tangible Assets
(93.06%) (36.70%) (34.60%) (23.94%) (14.92%) (82.34%) (132.30%) (263.38%) (159.94%) (281.51%)
Average Days of Receivables
— — — 0.00 0.00 0.00 0.00 0.00 0.00 —
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.15
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow per Share
(3.46) (2.51) (2.49) (2.46) (2.11) (15.35) (16.12) (32.72) (101.45) (328.28)
Cash per Share
4.81 8.48 10.53 13.14 17.50 52.58 22.39 37.83 111.88 187.99
Shareholders Equity per Share
4.57 8.52 10.82 13.97 17.71 36.02 23.22 31.75 106.75 188.85
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
4.57 8.52 10.82 13.97 17.71 36.02 23.22 31.75 106.75 188.85
Free Cash Flow
(29.78) (21.05) (20.95) (20.79) (16.48) (11.58) (9.14) (9.07) (6.59) (5.38)
Working Capital
37.36 69.49 86.98 112.63 138.11 27.10 13.00 8.63 6.67 2.21
Capital Expenditures
(0.02) (0.02) (0.01) (0.03) (0.01) (0.01) (0.01) (0.11) — (0.01)
Net Current Asset Value
37.36 69.49 86.98 112.63 138.11 27.10 12.99 8.63 6.67 2.21
Other line items
Quick Ratio
5.02 14.33 16.92 20.07 44.00 2.57 10.15 3.78 6.23 2.94
Depreciation/Fixed assets
0.00 0.00 0.00 0.00 0.00 2.24 1.53 0.81 11.22 5.51
Cash ROIC
(36.88%) (14.75%) (11.67%) (9.08%) (6.00%) (17.33%) (35.35%) (47.02%) (46.40%) (87.12%)
Accounts Receivable Turnover
— — — 0.00 0.00 0.00 0.00 0.00 0.00 —
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
— — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days of Inventory on Hand
— — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Revenue per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating CF per Share
(3.46) (2.51) (2.49) (2.46) (2.11) (15.34) (16.11) (32.32) (101.45) (327.72)
Capex per Share
0.00 0.00 0.00 0.00 0.00 (0.01) (0.01) (0.40) 0.00 (0.56)
Average Receivables
— — — 0.91 0.85 0.69 0.63 0.44 0.25 —
Average Payables
2.49 0.74 1.89 2.34 1.65 0.94 0.32 0.34 0.29 0.53
Average Assets
62.03 86.35 109.89 132.40 92.05 28.66 13.11 9.94 6.15 5.19
Average Common Equity
55.42 81.25 104.49 127.76 82.05 19.52 9.46 6.68 5.02 3.42
Capex to Sales
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 — 0.00

Fold the line items

Columns are period end dates · fundamentals updated 2 Oct 2026